Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a leading player in the biotechnology industry, is headquartered in the United States and focuses on developing innovative therapies for musculoskeletal health. Founded in 1983, Anika has achieved significant milestones, including the introduction of its proprietary hyaluronic acid-based products, which are designed to enhance joint health and improve patient outcomes. The company’s core offerings include viscosupplementation treatments and regenerative medicine solutions, setting it apart through its commitment to scientific excellence and patient-centric approaches. Anika Therapeutics has established a strong market position, recognised for its contributions to orthopaedics and sports medicine, and continues to expand its operational reach across major regions in North America and Europe. With a robust pipeline of products, Anika remains dedicated to advancing the field of therapeutic solutions for joint health.
DitchCarbon Score
How does Anika Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anika Therapeutics, Inc.'s score of 25 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Anika Therapeutics, Inc.'s reported carbon emissions
In 2023, Anika Therapeutics, Inc. reported total carbon emissions of approximately 3,164,000 kg CO2e, comprising 1,559,000 kg CO2e from Scope 1 and 2,085,000 kg CO2e from Scope 2 emissions. This data reflects a consistent emission profile compared to 2022, where the emissions were identical. Despite the stable emissions figures, Anika Therapeutics has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments or science-based targets indicates a potential area for improvement in their sustainability strategy. As a company headquartered in the US, Anika operates within an industry increasingly focused on climate action, and aligning with global standards could enhance their environmental impact and corporate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 1,559,000 | 0,000,000 |
| Scope 2 | 2,085,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Anika Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
